What biomarkers does Peter Attia emphasize?

Peter Attia emphasizes biomarkers that help assess atherosclerotic, metabolic, and dementia risk, while noting that biomarkers tell less about functional health and emotional well-being.

• ApoB: His key lipoprotein marker for atherosclerotic risk; he also highlights Lp(a) as an inherited risk factor that is generally worth checking once, and recommends considering ApoB early, especially with a concerning family history. 1 2 3
• Inflammation, endothelial health, and metabolic health markers: He includes these as useful blood-work categories for cardiovascular risk. He also links metabolic ill health—particularly hyperinsulinemia—with cancer risk, while stressing that blood biomarkers leave a substantial blind spot for cancer. 4
• Markers relevant to dementia and brain health: He says dementia-risk markers overlap with cardiovascular ones, and notes genetic testing can help stratify risk. He also discusses serum amyloid biomarkers for some high-risk patients, but cautions that their significance is less certain than cardiovascular markers. 5 6
• Hormone levels: He says he examines these in relation to physical health and performance, though he also favors functional assessments such as DEXA and exercise testing for understanding physical capacity. 7
• Not a settled aging biomarker: Attia says there are no reliable biomarkers for determining whether interventions such as fasting, metformin, or rapamycin are slowing aging. 8